Precision therapeutics to treat disease pathogenesis.


Anven’s DRx identifies and predicts drug responders to enrich clinical trial results.


Recent discoveries in biomimetic chemistry have enabled highly effective new approaches to definitively isolate the cause of disease and directly link gene-epitope-antibody relationships for systematically stratified immunotherapeutics.

 To learn more about Anven Biosciences and how our “proxy antigen” technology can help you develop effective treatments

for autoimmune or neurodegenerative diseases, please contact us.

The Science

Anven Technology 1.png
Anven Technology 2.png
Anven Technology 3.png
Anven Technology 4.png

Proxy antigens identify “antibody signatures”

Proxy antigen technology — a comprehensive tool to directly probe and profile an individual’s personal immune response related to specific disease states and specific drug interactions with unprecedented resolution.



Screen Shot 2019-05-16 at 11.03.25 AM.jpg

Drug Responder Signatures

The DRx predicts responders to specific drugs to enrich clinical trial recruitment.

Screen Shot 2019-07-28 at 6.09.10 PM.jpg


Rapid discovery of new precision therapeutics


Projects underway impacting:

  • Alzheimer’s Disease

  • Parkinson’s Disease

  • Cancer Immunotherapies (Ovarian, Prostate, Lung, Pancreatic, etc.)

  • Aging

  • Severe Depression

Anven’s platform works on a wide range of diseases. Contact us to discuss your project.


Let’s collaborate. Revive failed clinical trials.

Anven’s DRx identifies and predicts specific drug responders to obtain FDA approval;

  • Avoids millions of dollars of expense on non-responders

  • Saves time with early detection

  • Dramatically improves success

  • Fulfills hope for responding patients